Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal groups a and c and haemophilus b conjugate vaccine
- Development stage
- Phase 3
- Lead developer
- Zhifei Biological
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The meningococcal groups A and C and Haemophilus b conjugate vaccine is a combination vaccine developed by Beijing Zhifei Lvzhu Biopharmaceutical. It is designed to provide active immunization against invasive diseases caused by Neisseria meningitidis serogroups A and C, as well as Haemophilus influenzae type b (Hib). The vaccine consists of purified capsular polysaccharides from these three pathogens, each conjugated to a carrier protein (typically tetanus toxoid) to enhance immunogenicity, particularly in infants. A specific formulation, marketed as Xifibei, was the first triple conjugate vaccine approved in China. Recent clinical development has focused on evaluating adjuvant-free versions to compare safety and immunogenicity profiles against traditional adjuvanted formulations in the pediatric population.
- Brand names
- Xifibei
- Other names
- MenAC-Hib conjugate vaccineAC-Hib vaccineMeningococcal A and C and Haemophilus b conjugate vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharide
Beyond the preview
Go deeper on meningococcal groups a and c and haemophilus b conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal groups a and c and haemophilus b conjugate vaccine.